In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Prosthesis-patient mismatch after transcatheter mitral valve replacement

Session Moderated Cases 1: Acute heart failure, shock and more

Speaker Inmaculada Noval Morillas

Congress : Acute Cardiovascular Care 2019

  • Topic : imaging
  • Sub-topic : Echocardiography
  • Session type : Moderated Posters
  • FP Number : 27

Authors : I Noval Morillas (Cadiz,ES), A Chauca Tapia (Cadiz,ES), F Garcia Lanzas (Cadiz,ES), R Vazquez Garcia (Cadiz,ES)

15 views

Authors:
I Noval Morillas1 , A Chauca Tapia1 , F Garcia Lanzas1 , R Vazquez Garcia1 , 1University Hospital Puerta del Mar, Cardiology - Cadiz - Spain ,

Citation:

Introduction:
Mitral valve in valve is a minimally invasive transcatheter mitral valve replacement (TMVR) procedure for patients with deterioration of mitral bioprosthesis. Prosthesis-patient mismatch (PPM) can be considered after insertion into the patient when the effective orifice area (EOA) of the inserted prosthetic valve is smaller than expected EOA in relation to the patient's body surface area, which results in an increased postoperative transvalvular gradient. PPM after mitral valve replacement (MVR) has not been widely investigated. 
Clinical Case:
We present a 80 years-old woman with a 27 mm biological prosthesis implanted in 2010 due to combined severe mitral stenosis and mitral insufficiency, without residual pressure gradient across the mitral valve (4mmHg). The patient had not subsequent follow-up for personal reasons.
Five years later, she went to the emergency department due to progressive dyspnea. An urgent echocardiography was performed and it showed a degenerated and calcified biological prosthesis with increased gradients (11mmHg) and EOA calculated using continuity equation (VTI) of 0.96cm2.
Due to her high surgical risk, it was decided a transcatheter procedure (valve-in-valve) with a 21mm corevalve implantation in mitral position, through the transapical approach. After the intervention, the mean gradient across the mitral valve prosthesis was 10mmHg and indexed EOA <0.9cm2/m2. Two days after the procedure, the patient presented hemodynamic instability and shortness of breath. A transesophageal echocardiography (TEE) was performed, showing a severe increase in gradients across the mitral valve (23mmHg) and a thickening of one of the leaflet. Acute thrombosis on transcatheter mitral prosthesis was suspected, so it was decided to perform fibrinolysis at first, followed by treatment with intravenous heparian. One week later, a transthoracic echocardiogram (TTE) showed normal function of the prosthesis, despite similar gradients to those of the postoperative period; no image compatible with thrombus was observed, so she was diagnosed of severe prosthesis-patient mismatch. 
Conclusions:
Transcatheter mitral valve repair has been recognized as an alternative for treating patients with severe MR at high or prohibitive surgical risk. More recently, TMVR has emerged as another transcatheter option for treating MR. Although evidence on clinical outcomes and valve performance after TMVR is available, the information has been limited to procedural or short-term outcome results. Prevalence of PPM is different depending on the methods used to calculate EOA (continuity equation (CE), pressure half time (PHT) method…) ranging from 7% to 62%.  Some studies suggest that among the various methods used to define PPM, EOA by CE is the best predictor of postoperative hemodynamic parameters. Selecting a type of prosthetic valve with an appropriate EOA might be the only option to avoid mitral PPM and optimize the long-term outcomes of the MVR.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are